Dr Reddy's countersues AstraZeneca over purple pill

The company has alleged that AstraZeneca 'knew' about its plans to use the same colour in the capsules

Image via Shutterstock
<a href="http://www.shutterstock.com/pic-228848833/stock-photo-pills-drug.html" target="_blank">Image</a> via Shutterstock
Press Trust of India Hyderabad
Last Updated : Nov 20 2015 | 6:12 PM IST
Dr Reddy's Laboratories, which is embroiled in a legal battle with AstraZeneca over the usage of purple colour for generic version of Nexium, has filed a complaint in a US court alleging that the latter "knew" about its plans to use the same colour in the capsules.

Sources said Dr Reddy's has filed the petition against the Anglo-Swedesh firm AstraZeneca (AZ) in the District Court of New Jersey days after the Indian company was temporarily restrained by a US court from using purple colour for its generic version of Esomeprazole in the US market.

"DRL has countersued AstraZeneca for two reasons. One, it has taken objection to the fact that they cannot use purple colour and how anybody can object for using certain colour and the second and the important contention is that they (AZ) were always in the know that DRL will be using purple colour for the generic version of Esomeprozole," sources told PTI.

ALSO READ: Two US law firms threaten class action law suit against Dr Reddy's


On November 5, the US District Court of Delaware had issued the order based on a motion moved by AZ, objecting to the usage of the colour purple in the generic version of Nexium (Esomeprazole).

AstraZeneca argued that the purple pills (Prilosec and Nexium) have been famous for many years through extensive advertising both to doctors and patients, industry-leading commercial success, and extensive publicity, among other reasons.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Nov 20 2015 | 5:32 PM IST

Next Story